CVRX · Insider Trading
CVRx, Inc. Common Stock
Every open-market purchase and sale reported by CVRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Brent Binkowski | CHIEF OPERATING OFFICER | Buy | +26,223 | +$76.43K |
| 2026-08-13 | Brent Binkowski | CHIEF OPERATING OFFICER | Sell | −1,309 | −$3.34K |
| 2026-06-03 | Mudit K. Jain | Director | A | +8,720 | — |
| 2026-06-03 | Joseph P Slattery | Director | A | +8,720 | — |
| 2026-06-03 | Kevin J. Ballinger | Director | A | +8,720 | — |
| 2026-06-03 | Kirk G. Nielsen | Director | A | +8,720 | — |
| 2026-06-03 | Mitch C. Hill | Director | A | +8,720 | — |
| 2026-06-03 | Martha Shadan | Director | A | +8,720 | — |
| 2026-06-03 | Michael D Dale | Director | A | +29,005 | — |
| 2026-03-16 | Philip B. Adamson | Chief Medical Officer | MIXED | +39,738 | −$9.97K |
| 2026-03-04 | Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | A | +34,000 | — |
| 2026-03-03 | Robert Allen John | Chief Revenue Officer | MIXED | +31,036 | −$31.33K |
| 2026-03-03 | Brent Binkowski | CHIEF OPERATING OFFICER | A | +15,000 | — |
| 2026-03-03 | Kevin Hykes | PRES & CEO | MIXED | +151,237 | −$61.35K |
| 2026-03-03 | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | MIXED | +43,716 | −$10.15K |
| 2026-03-03 | Jared Oasheim | CHIEF FINANCIAL OFFICER | MIXED | +59,256 | −$13.78K |
| 2026-02-23 | Mudit K. Jain | Director | Buy | +46,800 | +$297.59K |
| 2026-02-18 | Mudit K. Jain | Director | Buy | +600 | +$2.79K |
| 2026-01-08 | Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | Sell | −44,674 | −$448.08K |
| 2025-12-01 | & Johnson Johnson | 10%+ Owner | Sell | −12,674 | −$127.12K |
| 2025-11-25 | & Johnson Johnson | 10%+ Owner | Sell | −5,400 | −$54.26K |
| 2025-11-14 | Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | Sell | −2,000 | −$20.00K |
| 2025-11-10 | & Johnson Johnson | 10%+ Owner | Sell | −105,064 | −$1.07M |
| 2025-08-13 | Brent Binkowski | CHIEF OPERATING OFFICER | A | +16,600 | — |
| 2025-06-05 | Mitch C. Hill | Director | A | +19,554 deriv. | — |
| 2025-06-05 | Joseph P Slattery | Director | A | +19,554 deriv. | — |
| 2025-06-05 | Mudit K. Jain | Director | A | +19,554 deriv. | — |
| 2025-06-05 | Martha Shadan | Director | A | +19,554 deriv. | — |
| 2025-06-05 | Kirk G. Nielsen | Director | A | +19,554 deriv. | — |
| 2025-06-05 | Kevin J. Ballinger | Director | A | +19,554 deriv. | — |
| 2025-05-19 | Kirk G. Nielsen | Director | Buy | +10,966 | +$59.80K |
| 2025-05-14 | Kirk G. Nielsen | Director | Buy | +187,813 | +$977.35K |
| 2025-05-13 | Mudit K. Jain | Director | Buy | +1,650 | +$7.77K |
| 2025-05-12 | Kevin Hykes | PRES & CEO | Buy | +5,000 | +$24.20K |
| 2025-03-04 | Robert Allen John | Chief Revenue Officer | A | +55,000 | — |
| 2025-03-04 | Jared Oasheim | CHIEF FINANCIAL OFFICER | A | +22,000 | — |
| 2025-03-04 | Philip B. Adamson | Chief Medical Officer | A | +20,000 | — |
| 2025-03-04 | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | A | +16,000 | — |
| 2025-03-04 | Kevin Hykes | PRES & CEO | A | +98,000 | — |
| 2024-11-21 | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | MIXED | +30 | −$6.56K |
| 2024-09-05 | Mitch C. Hill | Director | A | +36,136 deriv. | — |
| 2024-09-05 | Kevin J. Ballinger | Director | A | +36,136 deriv. | — |
| 2024-08-15 | Joseph P Slattery | Director | Buy | +3,000 | +$24.30K |
| 2024-08-08 | Joseph P Slattery | Director | Buy | +3,000 | +$24.72K |
| 2024-08-06 | Joseph P Slattery | Director | Buy | +2,500 | +$22.73K |
| 2024-08-05 | Kevin Hykes | PRES & CEO | Buy | +30,000 | +$250.77K |
| 2024-08-02 | Kevin Hykes | PRES & CEO | A | +180,000 deriv. | — |
| 2024-07-01 | Robert Allen John | Chief Revenue Officer | A | +122,192 deriv. | — |
| 2024-06-07 | Kirk G. Nielsen | Director | A | +27,250 deriv. | — |
| 2024-06-07 | Mudit K. Jain | Director | A | +27,250 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| & Johnson Johnson | 10%+ Owner | 4,040,861 | $5.74M |
| Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | 4,024,861 | $5.72M |
| Kirk G. Nielsen | Director | 1,918,854 | $2.72M |
| Mudit K. Jain | Director | 994,553 | $1.41M |
| Kevin Hykes | PRES & CEO | 284,237 | $403.62K |
| Jared Oasheim | CHIEF FINANCIAL OFFICER | 98,447 | $139.79K |
| Robert Allen John | Chief Revenue Officer | 86,036 | $122.17K |
| Philip B. Adamson | Chief Medical Officer | 61,578 | $87.44K |
| Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 60,551 | $85.98K |
| Joseph P Slattery | Director | 39,365 | $55.90K |
| Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | 34,000 | $48.28K |
| Brent Binkowski | CHIEF OPERATING OFFICER | 30,291 | $43.01K |
| Michael D Dale | Director | 29,005 | $41.19K |
| Kevin J. Ballinger | Director | 8,720 | $12.38K |
| Mitch C. Hill | Director | 8,720 | $12.38K |
| Martha Shadan | Director | 8,720 | $12.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.